Find a Clinical Trial

Showing 41 - 50 of 175 Trials

  • Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06513962

    Population:

    Pediatrics/Adult

    Phase:

    III
    Reproductive health outcomes, including the possibility of infertility from cancer treatment, are a major source of distress for adolescent and young adult (AYA) patients from diagnosis through survivorship. The overarching objective of this study is to investigate the impact of the Gonadotropin Releasing Hormone agonist (GnRHa) triptorelin, as a randomized intervention, on the ovarian reserve of newly diagnosed AYA cancer patients (exclusive of breast cancer) treated with alkylating agent chemotherapy. This trial is supported by the NCI Community Oncology Research Program (NCORP), led by the...

  • The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

    Principal Investigator:

    Catherine S Spina, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07097142

    Population:

    Adult

    Phase:

    III
    This study is being done to answer the following question: Is radiation given at higher doses over a shorter timeframe plus chemotherapy as good as the usual radiation and chemotherapy at preventing your bladder cancer from getting worse and avoiding bladder removal surgery? We are doing this study because we want to find out if this approach is the same as the usual approach for your bladder cancer. The usual approach for patients who are not in a study is treatment with surgery, radiation, or chemotherapy approved by the Food and Drug Administration (FDA). Sometimes, combinations of these...

  • An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM AGILE)

    Principal Investigator:

    Andrew B. Lassman, MD, FAAN, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03970447

    Population:

    Adult

    Phase:

    II/III
    The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called “study drugs” and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you...

  • A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04910685

    Population:

    Adult

    Phase:

    II/III
    You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you, with ISM and/or mMCAS. BLU-263 is not yet approved for treating ISM and/or mMCAS by the Food and Drug Administration (FDA). BLU-263 is the first study drug in a group of drugs that prevents a specific DNA change called KIT D816V. The goal...

  • AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05691478

    Population:

    Pediatrics/Adult

    Phase:

    II/III
    This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60 years with newly diagnosed early-stage cHL and will investigate the targeted CD30-antibody drug conjugate, Brentuximab Vedotin (Bv), with PD-1 blockade (nivolumab) compared with a standard chemotherapy regimen, with or without RT Are you...

  • A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

    Principal Investigator:

    Seda S Tolu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05416307

    Population:

    Adult

    Phase:

    II/III
    This study is testing an investigational drug called ELA026 in people who have a rare and serious immune condition called secondary hemophagocytic lymphohistiocytosis (sHLH). Investigational means that it is not approved by the United States Food and Drug Administration (FDA). sHLH causes the immune system to become overactive, leading to inflammation and damage to organs. ELA026 is designed to target specific immune cells that may contribute to the inflammation seen in sHLH. The study will also use dexamethasone, an FDA-approved steroid commonly used to help control inflammation. In this...

  • AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04322318

    Population:

    Pediatrics/Adult

    Phase:

    II
    This is a Phase 2 study of patients for the treatment of patients with high risk Wilms tumors (including those with diffuse anaplastic Wilms tumor- DAWT) and those who have relapsed favorable histology Wilms tumor (FHWT). The main goal of the study is to find out whether treatment with chemotherapy consisting of vincristine/irinotecan; cyclophosphamide/carboplatin/etoposide; and vincristine/doxorubicin/cyclophosphamide) improves the survival of patients with newly diagnosed Stage 4 diffuse anaplastic Wilms tumor (DAWT) or Standard-Risk relapsed favorable histology Wilms tumor (SRrFHWT) as...

  • A Phase 1/2 Study of DS-8201a in Children, Adolescents, or Young Adults with Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04616560

    Population:

    Pediatrics/Adult

    Phase:

    II
    The purpose of this study is to find out how well DS-8201a works in treating recurrent osteosarcoma (osteosarcoma that has come back after treatment) and what side effects is has on adolescents and young adults with HER2 positive recurrent osteosarcoma. The treatment involves giving DS-8201a through a vein (IV) once every 3 weeks. This 3 week time period is known as a cycle. You can receive up to 35 cycles (or about 24 months) of treatment as long as your tumor does not grow too much and you are not having any bad side effects. Are you Eligible? (Inclusion Criteria) Patients must have a...

  • AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04546399

    Population:

    Pediatrics/Adult

    Phase:

    II
    This is a study looking at how well the combination treatment of Blinatumomab and Nivolumab works in patients with first relapse of B-cell Acute Lymphoblastic Leukemia (B-ALL) as compared to treatment with only Blinatumomab. In addition, it is looking at what effects, good and/or bad the treatment has. First relapse means that B-ALL has come back after the initial treatment a patient received for B-ALL. All patients will receive treatment with Blinatumomab, an antibody (protein) that targets a marker on B-ALL cells and then uses your immune system to kill the B-ALL cell. Some patients will...

  • Audiovisual Didactic Experience for Latino patient treatment Adherence and Non-English speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology

    Principal Investigator:

    Lisa Ann Kachnic, MD, FASTRO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05351424

    Population:

    Adult

    Phase:

    II
    In this study, you will be randomized to receive either a brochure or watch a video that discusses radiation and cancer clinical trials. In addition, you will complete questionnaires at seven time points: 1 questionnaire before radiotherapy, 4 questionnaires during the course of radiotherapy and 2 questionnaires at follow-up visits. The questionnaires and brochure or video administration will take place during your standard of care visits. Are you Eligible? (Inclusion Criteria) To be included in the main study, you must: 1. be age 18 years or older 2. be Spanish speaker of Latino Background...

Pages

Back to top